# CAR T-Cells That Fight Ovarian and Prostate Cancer by Targeting LHR

> This patent describes a new type of CAR T-cell therapy designed to fight ovarian and prostate cancers by specifically targeting the Luteinizing Hormone Receptor (LHR) protein found on cancer cells.

- **Patent:** US 20250129171
- **Original title:** Car t-cell therapy directed to lhr for the treatment of solid tumors
- **Owner:** University of Southern California
- **Status:** Active
- **Times cited:** 0
- **Field:** biotech, pharmaceutical, gene_editing, oncology

## What it does

This patent describes a Chimeric Antigen Receptor (CAR) that specifically targets the Luteinizing Hormone Receptor (LHR) protein. This CAR is made up of several parts: an "antigen binding domain" from an anti-LHR antibody (using specific heavy and light chain variable regions, like SEQ ID NO.: 3 and 7), a "hinge domain," a "transmembrane domain," a "costimulatory signaling region," and a "CD3 zeta signaling domain" (Claim 1). These CARs are then put into immune cells, typically T-cells or Natural Killer (NK) cells (Claim 8), making them into a targeted therapy. When these modified T-cells or NK cells encounter cancer cells that have LHR on their surface, they are designed to attack and inhibit the growth of those cancer cells (Claim 11, 13). For example, a patient with prostate cancer that expresses LHR could receive these modified T-cells to specifically target and destroy their tumor cells.

## What it does NOT cover

- CAR T-cell therapies that target cancer proteins other than the Luteinizing Hormone Receptor (LHR).
- CAR T-cells that do not include all the specified components, such as a hinge domain, transmembrane domain, costimulatory signaling region, and CD3 zeta signaling domain.
- CAR T-cells where the antigen binding domain does not use the specific antibody sequences (SEQ ID NO.: 3 and 7) or sequences with at least 90% identity to them.
- Methods of treating cancers that do not express or overexpress the LHR protein.
- Traditional chemotherapy, radiation therapy, or surgical methods for cancer treatment.

## The clever bit

The clever bit is identifying and validating the Luteinizing Hormone Receptor (LHR) as a specific and effective target for CAR T-cell therapy in solid tumors like ovarian and prostate cancer. This patent provides the precise genetic blueprints (specific antibody sequences) needed to engineer T-cells to recognize and attack LHR-expressing cancer cells.

## Real-world examples

1. Kymriah (Novartis, a CAR T-cell therapy for blood cancers)
2. Yescarta (Gilead, a CAR T-cell therapy for blood cancers)
3. Prostate cancer treatments
4. Ovarian cancer treatments
5. Antibody-drug conjugates (another form of targeted therapy)

## Why it matters

Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of certain blood cancers, but treating solid tumors like ovarian and prostate cancer remains a significant challenge. This patent focuses on a novel approach to target LHR, a protein found on some solid tumor cells, potentially opening new avenues for treatment. By providing specific antibody sequences, it lays a foundation for developing precise immunotherapies against these hard-to-treat cancers.

## Frequently asked questions

### What does CAR T-Cells That Fight Ovarian and Prostate Cancer by Targeting LHR cover?

This patent describes a new type of CAR T-cell therapy designed to fight ovarian and prostate cancers by specifically targeting the Luteinizing Hormone Receptor (LHR) protein found on cancer cells.

### Who owns patent US 20250129171?

This patent is owned by University of Southern California.

### When does this patent expire?

This patent is expected to expire on May 20, 2044, when the invention enters the public domain.

### What problem does this patent solve?

Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of certain blood cancers, but treating solid tumors like ovarian and prostate cancer remains a significant challenge. This patent focuses on a novel approach to target LHR, a protein found on some solid tumor cells, potentially opening new avenues for treatment. By providing specific antibody sequences, it lays a foundation for developing precise immunotherapies against these hard-to-treat cancers.

### What does this patent NOT cover?

CAR T-cell therapies that target cancer proteins other than the Luteinizing Hormone Receptor (LHR).

**Full plain-English explainer:** https://patentbrief.org/patent/us/20250129171/car-t-cell-therapy-directed-to-lhr-for-the-treatment-of-solid-tumors

**Original patent:** https://patents.google.com/patent/US20250129171

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._


## Related patents

Semantically similar inventions in the PatentBrief corpus:

- [How Genetically Modified T-Cells Attack Cancer](https://patentbrief.org/patent/us/9328156/use-of-chimeric-antigen-receptor-modified-t-cells-to-treat-cancer) — This patent describes how human T cells are genetically engineered to express a special receptor (CAR) that specifically targets and kills cancer cells, particularly those with the CD19 marker, offering a new way to treat cancer.
- [Targeting Cancer with CAR T Cells Using a Chemical Tag](https://patentbrief.org/patent/us/20240165159/compositions-and-methods-for-car-t-cell-therapy) — This patent describes a method to treat cancer by giving a patient special immune cells (CAR T cells) that recognize a chemical tag, which is attached to a small drug molecule, along with a separate folate compound.
- [How Genetically Modified T-Cells Fight CD19 Cancers](https://patentbrief.org/patent/us/9481728/compositions-and-methods-for-treatment-of-cancer) — This patent describes how to create and use genetically modified human T cells that target and kill cancer cells expressing the CD19 protein, offering a new way to treat blood cancers.
- [Treating a Specific Lymphoma with Modified T Cells](https://patentbrief.org/patent/us/12600775/chimeric-antigen-receptor-t-cell-therapy) — This patent describes a method to treat a difficult-to-treat type of lymphoma by taking a patient's own immune cells, modifying them to recognize and attack cancer, and then giving them back to the patient.
- [Using Antibodies and CAR-T Cells to Fight MUC1-C Expressing Cancers](https://patentbrief.org/patent/us/12735503/anti-muc1-c-antibodies-and-car-t-structures) — This patent describes specific antibodies and engineered immune cells (CAR-T) designed to target and treat cancers that produce a particular protein called MUC1-C.
